- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05265793
Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma
A Multicenter, Open, Single Arm, Phase II Clinical Study of Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Xiaowei Zhang, Doctor
- Phone Number: 88503 021-64175590
- Email: dongfangzhizizhxw@aliyun.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Recruiting
- Fudan University Shanghai Cancer Center
-
Contact:
- Xiaowei Zhang, Doctor
- Phone Number: 520 021-64175590
- Email: dongfangzhizizhxw@aliyun.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 ~ 75 years old, and gender is not limited;
- Advanced patients with sarcomatoid carcinoma or carcinosarcoma confirmed by histopathology;
- Patients with sarcomatoid carcinoma who have not received systematic drug treatment or have received first-line treatment;
- The physical condition score (PS) of Eastern cancer cooperation group (ECoG) was 0 ~ 2;
- The expected survival time is more than 3 months;
- Within 7 days (including 7 days) before screening, the laboratory test data shall be Calculation: neutrophil count ≥ 1.5 × 109 / L, platelet count ≥ 90 × 109 / L, hemoglobin ≥ 90g / L (no blood transfusion within 14 days), total serum bilirubin ≤ 1.25 times the upper limit of normal (ULN); ALT and AST ≤ 2.5 x ULN (patients with liver metastasis ≤ 5x ULN); Serum creatinine ≤ 1.25 x ULN;
- Measurable lesions (RECIST 1.1 standard);
- The subjects (or their legal representative / Guardian) must sign the informed consent form, indicating that they understand the purpose of the study, understand the necessary procedures of the study, and are willing to participate in the study.
Exclusion criteria
Those who have one or more of the following are not eligible for this study:
- Patients who have previously received anti-vascular targeted drugs or PD-1 mAb;
- Received any experimental drugs or antitumor drugs within 4 weeks before enrollment; History of other tumors in the past five years, except cured cervical cancer or skin basal cell carcinoma;
- Symptomatic brain or meningeal metastasis (unless the patient has received treatment for > 6 months, the imaging result is negative within 4 weeks before entering the study, and the clinical symptoms related to the tumor are stable at the time of entering the study);
- Clinically significant active bleeding;
- Pregnant or lactating women; Those who are fertile and do not take adequate contraceptive measures;
- Alcohol or drug addiction;
- Patients with active or history of autoimmune diseases that may recur (such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune thyroid disease, multiple sclerosis, vasculitis, glomerulitis, etc.), or patients with high risk (such as organ transplantation and immunosuppressive treatment). Except for autoimmune hypothyroidism requiring hormone replacement therapy only or skin diseases without systemic treatment.
- Patients requiring systemic corticosteroids (equivalent to > 10mg prednisone / day) or other immunosuppressive drugs within 14 days before enrollment or during the study. Use topical or inhaled glucocorticoids, or use glucocorticoids for short-term (≤ 7 days) to prevent or treat non autoimmune and infrequent allergic diseases.
- Important organ failure or other serious diseases, including interstitial pneumonia, clinically related coronary artery disease, cardiovascular disease, or myocardial infarction, congestive heart failure, unstable angina pectoris, symptomatic pericardial effusion or unstable arrhythmia within 6 months before enrollment;
- Have a history of infection with human immunodeficiency virus, or suffer from other acquired and congenital immunodeficiency diseases, or have a history of organ transplantation or stem cell transplantation;
- Patients with chronic hepatitis B or active hepatitis C. HBV carriers, stable hepatitis B after treatment (DNA titer less than 103 copies /ml) and cured hepatitis C patients (negative for HCV RNA test) can be enrolled.
- Serious neurological or psychiatric history; Severe infection; Active disseminated intravascular coagulation or other concomitant diseases that seriously endanger the safety of the patient or affect the completion of the study according to the judgment of the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Camrelizumab Combined With Apatinib
Apatinib tablets: 250mg qd.po, 4 weeks as a cycle, continuous medication until disease progression, death or intolerable toxicity; Camrelizumab: administered intravenously with a fixed dose of 200mg, administered intravenously (without preventive medication), each infusion for 30min (no less than 20min, no more than 60min), administered once every two weeks until disease progression, death or intolerable toxicity. The maximum period is 2 years. The curative effect was evaluated every 8 weeks. |
After signing the informed consent, the selected patients received Camrelizumab combined with Apatinib.
Treatment until disease progression and intolerable adverse reactions occur
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR
Time Frame: the rate of patients with CR and PR, through study completion, an average of 1 year
|
objective response rate
|
the rate of patients with CR and PR, through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
OS
Time Frame: from the time signing of ICF until the date of death from any cause, assessed up to 36 months
|
overall survival
|
from the time signing of ICF until the date of death from any cause, assessed up to 36 months
|
PFS
Time Frame: from the time signing of ICF until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months
|
progression free survival
|
from the time signing of ICF until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months
|
AE
Time Frame: the adverse events rate and types of all enrolled patients, through study completion, an average of 1 year
|
the adverse events of all enrolled patients
|
the adverse events rate and types of all enrolled patients, through study completion, an average of 1 year
|
DCR
Time Frame: the rate of patients with CR, PR and SD, through study completion, an average of 1 year
|
disease control rate
|
the rate of patients with CR, PR and SD, through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Neoplasms, Complex and Mixed
- Sarcoma
- Carcinoma
- Carcinosarcoma
- Mixed Tumor, Mullerian
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Apatinib
Other Study ID Numbers
- FDCC-SC-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinosarcoma
-
University of Alabama at BirminghamWithdrawnCarcinosarcoma of Ovary | Carcinosarcoma of Uterus | Carcinosarcoma of VaginaUnited States
-
Fondazione Policlinico Universitario Agostino Gemelli...CompletedCarcinosarcoma, Ovarian | Carcinosarcomas UterineItaly
-
Abramson Cancer Center of the University of PennsylvaniaCompletedCarcinoma of the Cervix, Carcinoma or Carcinosarcoma of the UterusUnited States
-
University of OklahomaEli Lilly and CompanyActive, not recruitingCarcinosarcoma, OvarianUnited States
-
North Eastern German Society of Gynaecological...Novartis Pharmaceuticals; medac GmbHActive, not recruiting
-
Assuta Medical CenterUnknownProstate Carcinosarcoma
-
Memorial Sloan Kettering Cancer CenterMerck Sharp & Dohme LLCRecruitingUterine Carcinosarcoma | Advanced Uterine CarcinosarcomaUnited States
-
Yonsei UniversityRecruitingRecurrent/Metastatic CarcinosarcomaKorea, Republic of
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedSarcomaUnited States, Japan
-
Australia New Zealand Gynaecological Oncology GroupMerck Sharp & Dohme LLC; Eisai Inc.RecruitingUterine Carcinosarcoma | Ovarian CarcinosarcomaCanada, Australia, United Kingdom
Clinical Trials on Camrelizumab Combined With Apatinib
-
Sun Yat-sen UniversityJiangsu HengRui Medicine Co., Ltd.RecruitingC-staged Hepatocellular Carcinoma in BCLC ClassificationChina
-
Guangxi Medical UniversityJiangsu HengRui Medicine Co., Ltd.RecruitingHepatocellular CarcinomaChina
-
First Affiliated Hospital Xi'an Jiaotong UniversityJiangsu HengRui Medicine Co., Ltd.UnknownLocally Advanced Gastric CancerChina
-
Henan Provincial People's HospitalNot yet recruiting
-
Yongyi ZengNot yet recruitingHepatocellular Carcinoma
-
Sun Yat-sen UniversityJiangsu HengRui Medicine Co., Ltd.RecruitingC-staged Hepatocellular Carcinoma in BCLC ClassificationChina
-
The Second Affiliated Hospital of Shandong First...Recruiting
-
The First Affiliated Hospital of Zhengzhou UniversityRecruitingEsophageal Cancer by AJCC V8 StageChina
-
Hunan Cancer HospitalJiangsu Hengrui Pharmaceuticals Co.,LtdRecruitingHepatocellular Carcinoma | Immune Checkpoint InhibitorsChina